Survival of biological therapeutics in psoriasis: Retrospective analysis of 3-years data in a Turkish Registry, PSORTAKSIS.

BACKGROUND/AIM PSORTAKSIS is a psoriasis registry, is used for follow-up of patients in Kayseri City Education and Research Hospital, Dermatology Clinic since 2016 in Turkey. PSORTAKSIS includes demographic data, follow-up clinical findings, laboratory output, and treatment information of patients. Here, drug survivals of biologic therapeutics (BT) according to three-year data of PSORTAKSIS will be presented. MATERIALS AND METHODS Drug survival of BT in PSORTAKSIS was analyzed from 2016 to March 2019. RESULTS 158 patients (111 of them BT-naive) with psoriasis under BT were enrolled in the current study. Drug survival analysis of patients with ongoing BT (158 treatment periods) revealed mean survival time as; 15.49 months for ustekinumab, 15.37 months for adalimumab, 14.00 months for etanercept, 5 months for infliximab, and 4.59 months for secukinumab. The differences between drug survivals of BT were statistically significant (log-rank test, ?2 = 79.915, p<0.0001). Age of onset was found to be the only independent risk factor of drug survival according to regression analysis (p=0.029). CONCLUSION As a conclusion, drug survival of UST was significantly higher than that of TNF-alpha inhibitors and SEC in the treatment of psoriasis. This study revealed that among predictors, age at disease onset may influence drug survival.